<DOC>
	<DOCNO>NCT01887327</DOCNO>
	<brief_summary>Neonatal jaundice common cause hospital readmission term- near term infant management pose significant burden healthcare system . Infants isoimmune hemolytic disease , ABO Rhesus ( Rh ) incompatibility , glucose-6-phosphate dehydrogenase ( G6PD deficiency ) , increased rate red cell destruction , thus , increase bilirubin production . Newborn infant immature liver function conjugate bilirubin well , result accumulation unconjugated bilirubin . Thus , bilirubin level may rise rapidly intervention may require . At present , phototherapy ( PT ) frequently use treatment hyperbilirubinemia ; convert unconjugated bilirubin less toxic water soluble photoisomers excrete urine without need conjugation . Infants respond PT treat exchange transfusion ( ET ) , consider therapy last resort associate morbidity mortality . Both PT ET enhance elimination , impact production bilirubin . Stannsoporfin heme oxygenase inhibitor act reduce bilirubin production . It develop management neonatal jaundice .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Two Doses Stannsoporfin Combination With Phototherapy Neonates With Hyperbilirubinemia</brief_title>
	<detailed_description />
	<mesh_term>Jaundice</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Hyperbilirubinemia , Neonatal</mesh_term>
	<mesh_term>Jaundice , Neonatal</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>1 . Term near term infant ≥35 ≤ 43 week GA , age 048 hour ABO Rh incompatibility ( anti C , c , D , E e ) Coombs positive , age 072 hour G6PD deficiency 2 . Parental guardian consent 3 . Birth weight ≥ 2500 gram 4 . At agespecific threshold initiate PT per AAP guideline base measurement TSB 5 . Parents agree observe light precaution 10 day post treatment 1 . Elevated direct bilirubin ≥2 mg/dL , OR &gt; 20 % total serum bilirubin 2 . Alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) and/or aspartate aminotransferase ( AST ) &gt; 3 time ULN 3 . Abnormal renal function define creatinine and/or blood urea nitrogen &gt; 2 time ULN 4 . Any clinically significant abnormality screen laboratory evaluation ( include ECG ) opinion investigator make patient unsuitable clinical trial 5 . Apgar score ≤6 age 5 minute 6 . An unexplained exist rash skin erythema 7 . Prior exposure PT 8 . Clinical suggestion neonatal thyroid disease current uncontrolled thyroid disease mother ( maternal Hashimoto 's disease exclusionary ) 9 . Cardiorespiratory distress , define respiratory rate &gt; 60 breath per minute time enrollment 10 . Any abnormal auditory ophthalmologic finding screen physical exam 11 . Treatment need treatment neonate medication photoreactive may prolong QT interval ( erythromycin ointment eye prophylaxis permit ) , family history Long QT syndrome QT syndrome ( appendix C ) 12 . Known porphyrias risk factor porphyrias , include family history 13 . A maternal history systemic lupus erythematosus 14 . Maternal use phenobarbital 30 day , delivery , breastfeed 15 . Maternal current drug alcohol abuse , maternal history drug alcohol abuse , opinion Investigator , would make patient suitable candidate participation clinical trial 16 . Significant congenital anomaly infection 17 . Risk require surgery exposure operate room ( OR ) light first 2 week life 18 . Persistent hypoglycemia ( blood glucose &lt; 40 mg/dL ) 19 . Temperature instability define temperature consistently ( 3 consecutive time ) &lt; 36ºC and/or &gt; 37.5ºC axillary 20 . Use IVIG albumin prior study drug administration 21 . Postdelivery treatment medication know suspected displace bilirubin albumin ( e.g. , ceftriaxone sulfabased antibiotic ) 22 . Use photosensitize drug agent ( appendix D ) 23 . Unwillingness parents/guardians adhere recommendation regard light precaution 24 . Exposure investigational medication device delivery , participation another clinical trial participate trial 25 . Any concurrent medical condition , opinion Investigator , make patient unsuitable clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Hours</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>G6PD deficiency</keyword>
	<keyword>ABO incompatibility</keyword>
	<keyword>Coombs positive ABO/RH incompatibility</keyword>
	<keyword>intensive phototherapy neonate</keyword>
	<keyword>Hyperbilirubinemia</keyword>
	<keyword>Neonatal Jaundice</keyword>
</DOC>